Mode
Text Size
Log in / Sign up

Intranasal Dexmedetomidine Plus Midazolam Improves Sedation Success Versus Chloral Hydrate in ChildrenDexmedetomidine Plus Midazolam Works Better for Kids

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider dexmedetomidine plus midazolam for higher sedation success, noting faster onset with chloral hydrate and events.

This single-center randomized controlled trial study evaluated 180 children aged 1–6 years with American Society of Anesthesiologists physical status I–II undergoing outpatient procedural sedation procedures specifically. The intervention involved intranasal dexmedetomidine combined with oral midazolam, compared against intranasal dexmedetomidine combined with oral chloral hydrate. The primary outcome of first-attempt sedation success was significantly higher in the dexmedetomidine plus midazolam group at 95.56% versus 86.67% in the comparator group (P = 0.036, statistically significant). Sedation onset time was shorter in the dexmedetomidine plus chloral hydrate group (P < 0.001) but recovery time was comparable overall.

Peri-sedation adverse events were comparable between groups. However, incidence of somnolence, ataxia, and any adverse event within 0–48 h after discharge was significantly higher in the dexmedetomidine plus chloral hydrate group (all P < 0.05). Children’s medication acceptance and parental satisfaction were significantly lower in the dexmedetomidine plus chloral hydrate group (P < 0.001). Recovery time was clearly comparable between the two groups overall.

Multivariable analysis confirmed the dexmedetomidine plus midazolam regimen was independently and significantly associated with lower risks of several post-discharge adverse events but a higher risk of behavioral changes. Serious adverse events were also not reported in the final study data.

Lena’s son was scheduled for an MRI. He’s three, scared of loud noises, and couldn’t stay still. Like thousands of parents each year, she worried: Will the sedation work? What if something goes wrong after we go home?

Sedation is common in young children who need imaging tests like MRIs or CT scans. These tests require total stillness. But kids under six often can’t cooperate — not because they’re defiant, but because they’re too young to understand.

Doctors use medicine to help them relax or sleep during the test. The goal is simple: keep the child safe, calm, and still — with as few side effects as possible.

One combo has been popular for years: intranasal dexmedetomidine plus oral chloral hydrate. It’s used widely because both drugs are available and familiar.

But here’s the twist: a newer mix may be safer and more effective — even though it’s been around just as long.

Dexmedetomidine plus midazolam wins on key measures

The brain is like a busy control center. Signals fly between nerve cells, telling the body to move, feel, or stay calm. Sedatives work by slowing down this traffic.

Think of it like lowering the volume on a loud stereo. Dexmedetomidine turns down alertness by targeting a specific “volume knob” in the brainstem. Midazolam boosts a calming chemical, like adding a soothing playlist. Chloral hydrate also calms the brain, but in a less precise way — more like turning off the stereo entirely.

The mix matters — because how fast the drugs work, how long they last, and how they affect behavior all depend on the combination.

A recent trial tested two common combos in 180 children aged 1 to 6. All needed outpatient sedation for imaging or minor procedures.

Half got dexmedetomidine through the nose plus chloral hydrate by mouth. The other half got the same nose spray but with midazolam instead.

The results were clear.

First-attempt success — meaning the child stayed still and the test worked without extra drugs — happened in 96 out of 100 kids given midazolam.

With chloral hydrate, it worked on the first try for only 87 out of 100.

That difference may sound small. But in real terms, it means one in ten kids on chloral hydrate needed more medicine, more time, or had to reschedule — adding stress for families and clinics.

Recovery time was similar. But kids on chloral hydrate were more likely to feel sleepy, wobbly, or confused after going home.

Within 48 hours, parents reported more side effects — like trouble walking or staying awake — in the chloral hydrate group.

Parents also rated their experience lower. Many said their child resisted taking chloral hydrate because of the taste.

Midazolam was easier to give. Kids accepted it more often. Parents were more satisfied.

But there’s a catch.

The midazolam group had more reports of short-term behavior changes — like irritability, crying, or confusion — after the procedure.

These didn’t last long. But they were noticeable enough that caregivers should be warned.

Experts say this makes sense. Midazolam affects memory and mood centers more directly. While it helps with sedation, it can briefly alter how a child acts — especially when waking up.

Still, the overall balance favors midazolam. Fewer side effects at home, higher success rates, and better family experience.

This doesn't mean this treatment is available yet.

Wait — it already is. Both drugs are approved. Many hospitals already use this combo.

So why does this matter? Because chloral hydrate is still widely used — often out of habit, not evidence.

This study gives doctors clear data to switch.

There are limits, though. The trial was done at one hospital. All kids were healthy with no major medical issues. Results might differ for children with developmental delays or chronic illness.

Also, the study didn’t track kids beyond 48 hours. Long-term effects weren’t measured — though neither drug is known to cause lasting harm.

What happens next? Larger multi-center trials could confirm these results across different settings. Guidelines may soon update to recommend midazolam over chloral hydrate when combined with dexmedetomidine.

For now, parents don’t need to demand a specific drug. But they can ask: What sedation plan do you recommend? What are the common side effects after we go home?

That conversation could make the difference between a smooth visit and a stressful one.

And for clinics still using chloral hydrate — the evidence is growing. It may be time to change the script.

Research takes time. But sometimes, the best answer isn’t something new — it’s using what we already have, more wisely.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BackgroundCombination sedation regimens are widely used in pediatric procedural sedation. However, the efficacy and incidence of post-discharge adverse events between intranasal dexmedetomidine combined with oral chloral hydrate and intranasal dexmedetomidine combined with oral midazolam remain unclear.MethodsThis was a single-center, prospective, randomized controlled trial. A total of 180 children aged 1–6 years with American Society of Anesthesiologists physical status I–II who were scheduled for outpatient procedural sedation between December 2022 and October 2023 were enrolled and randomly assigned to receive intranasal dexmedetomidine combined with oral chloral hydrate (D+C group, n = 90) or intranasal dexmedetomidine combined with oral midazolam (D+M group, n = 90). The primary outcome was first-attempt sedation success. Secondary outcomes included the incidence of caregiver-reported post-discharge adverse events within 48 h, the incidence of peri-sedation adverse events, sedation onset time, procedure duration, recovery time, children’s medication acceptance, and parental satisfaction.ResultsThe first-attempt sedation success rate was significantly higher in the D+M group than in the D+C group (95.56% vs. 86.67%, P = 0.036). Sedation onset time was shorter in the D+C group (P < 0.001), whereas recovery time and peri-sedation adverse events were comparable between the two groups. Children’s medication acceptance and parental satisfaction were lower in the D+C group (P < 0.001). During the 0–48 h period after discharge, the D+C group had higher incidences of somnolence, ataxia, and any adverse event (all P < 0.05). Multivariable analysis confirmed that the D+M regimen was independently associated with lower risks of several post-discharge adverse events but a higher risk of behavioral changes. Phi coefficient analysis suggested clustering of adverse events, with neurologic symptoms tending to co-occur.ConclusionCompared with the D+C regimen, the D+M regimen provides a higher first-attempt sedation success rate and fewer post-discharge adverse events, although attention to post-discharge behavioral changes remains necessary.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.